Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
Triple data take Nuvalent's market cap above $3bn
After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.
